Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Akebia Therapeutics (AKBA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Shares of AKBA Up 39.6% Since Uptrend Call on Shares

SmarTrend identified an Uptrend for Akebia Therapeut (NASDAQ:AKBA) on December 20th, 2016 at $10.03. In approximately 7 months, Akebia Therapeut has returned 39.58% as of today's recent price of $14.00....

AKBA : 13.82 (+1.10%)
Akebia Therapeut Has Returned 44.2% Since SmarTrend Recommendation (AKBA)

SmarTrend identified an Uptrend for Akebia Therapeut (NASDAQ:AKBA) on December 20th, 2016 at $10.03. In approximately 7 months, Akebia Therapeut has returned 44.17% as of today's recent price of $14.46....

AKBA : 13.82 (+1.10%)
Akebia Announces Closing of Public Offering of Common Stock and Exercise of Option by Underwriters

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

MS : 46.59 (+0.17%)
AKBA : 13.82 (+1.10%)
Akebia Announces Pricing of Public Offering of Common Stock

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

MS : 46.59 (+0.17%)
AKBA : 13.82 (+1.10%)
Uptrend Call Working As Akebia Therapeut Stock Rises 61.7% (AKBA)

SmarTrend identified an Uptrend for Akebia Therapeut (NASDAQ:AKBA) on December 20th, 2016 at $10.03. In approximately 6 months, Akebia Therapeut has returned 61.71% as of today's recent price of $16.22....

AKBA : 13.82 (+1.10%)
Akebia Therapeutics to Host Analyst and Investor Day on June 27, 2017

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor...

AKBA : 13.82 (+1.10%)
Technical Insights on Biotech Stocks -- Soligenix, Sorrento Therapeutics, Alcobra, and Akebia Therapeutics

On Thursday, benchmark US indices were in bullish colors as the NASDAQ Composite closed the trading session up 0.39%; the Dow Jones Industrial Average edged 0.04% higher; and the S&P 500 was up 0.03%....

SRNE : 2.05 (unch)
ADHD : 1.13 (-0.88%)
AKBA : 13.82 (+1.10%)
SNGX : 2.68 (-6.62%)
SNGXD : 4.1500 (-5.68%)
Biotech Stock Roundup: Biogen Inks Deal to Boost Pipeline, Sangamo Soars on Pfizer Deal

Quite a few deals were announced this week including by companies like Biogen (BIIB).

SGMO : 9.50 (-0.52%)
AKBA : 13.82 (+1.10%)
VRTX : 163.17 (+2.41%)
IONS : 56.39 (+0.95%)
REGN : 515.92 (-1.00%)
ALXN : 131.79 (+1.53%)
BIIB : 282.92 (+0.53%)
Vifor Pharma and Akebia Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval

Vifor Pharma Ltd. / Vifor Pharma and Akebia Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval . Processed and transmitted by Nasdaq Corporate...

AKBA : 13.82 (+1.10%)
Akebia and Vifor Pharma Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval

--- Additional Funds Support Vadadustat Global Development Program to Data a^'

AKBA : 13.82 (+1.10%)
Akebia Announces First Quarter 2017 Financial Results

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 13.82 (+1.10%)
Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 13.82 (+1.10%)
Akebia Therapeutics (AKBA) Shows Strength: Stock Up 5.8%

Akebia Therapeutics, Inc. (AKBA) shares rose almost 6% in the last trading session.

AKBA : 13.82 (+1.10%)
GRFS : 20.70 (-1.05%)
American Kidney Fund Receives Funding Support to Expand Popular 'ACT on Anemia' Education Program to Reach Spanish Speakers

The American Kidney Fund (AKF) today announced it has received funding support to expand its popular "ACT on Anemia" program by creating new Spanish-language web content and educational materials, along...

AKBA : 13.82 (+1.10%)
Akebia and Otsuka Expand Relationship with Collaboration to Develop and Commercialise Vadadustat in Europe, China and Other Territories

--- Committed Capital and Potential Milestone Payments from Otsuka of up to $865 Million, including $208 million or more in Upfront Payment and Development Funding, as well as Tiered, Double-Digit Royalties...

AKBA : 13.82 (+1.10%)
Akebia and Otsuka Expand Relationship with Collaboration to Develop and Commercialize Vadadustat in Europe, China and Other Territories

--Committed Capital and Potential Milestone Payments from Otsuka of up to $865 Million, Including $208 million or More in Upfront Payment and Development Funding, as well as Tiered, Double-Digit Royalties...

AKBA : 13.82 (+1.10%)
Akebia Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 13.82 (+1.10%)
Akebia to Present at the 16th Annual Needham Healthcare Conference

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 13.82 (+1.10%)
Akebia Announces Publication of Phase 2a Results for Vadadustat in Patients with Anemia Related to Chronic Kidney Disease

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 13.82 (+1.10%)
Akebia Announces Fourth Quarter and Full-Year 2016 Financial Results

Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible...

AKBA : 13.82 (+1.10%)

Van Meerten Stock Picks

5 Great Growth Stocks
Each week Value Line publishes a list of growth stocks the for the past 10 years have had a 10% increase in Sales, Cash Flow, Earnings, Dividends and Book Value and are expected to continue that 10% growth for the next 5 years.
NVDA +0.60 , CGNX +1.53 , EDU -1.50 , LUV -0.12 , ZBRA -1.17
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Sep E-mini S&Ps this morning are down -0.05% and the dollar index sold-off to a 1-year low on concern the Trump administration's economic agenda may be stalled as U.S. special counsel Mueller is said to be... Read More

Chart of the Day

TRI Pointe Homes (TPH) is a high growth stock that has a Trend Spotter buy signal and double digit projections for both Revenue and earnings.
Read More

Brugler Ag Report

Today's Commentary

Corn futures closed Friday with losses of 7 to 11 1/4 cents in most contracts, with Sep gaining 3 1/2 cents on the week. Friday morning showed showers rolling across dry portions of Northern NE and Southern SD. Recent bulls were cashing out rather th...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.